Careful Scrutiny Of Leadless Pacemaker Adverse Events Urged By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
As the agency prepares for PMA submissions from Medtronic and St. Jude for first-to-market leadless pacemakers, its advisory panel emphasized the importance of large and long post-approval studies that single out individual adverse event types for measurement.